A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.
NN6705-8141
Phase 1 other active
Quick answer
A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation. for Cardiometabolic diseases with an inflammatory component is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Cardiometabolic diseases with an inflammatory component
- Phase
- Phase 1
- Modality
- other
- Status
- active